Current Report Filing (8-k)
May 07 2021 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 6, 2021
|
INMUNE BIO INC.
|
|
|
(Exact name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
1200 Prospect Street, Suite 525, La
Jolla, CA 92037
(Address of Principal Executive Offices)
(Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per shares
|
|
INMB
|
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other
Events.
INmune Bio Inc. (the “Company”) is filing as Exhibit 99.1 to this Current Report on Form 8-K the script to the Company’s
earnings call that was held on May 6, 2021.
Item 9.01 Financial
statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMUNE BIO INC.
|
|
|
Date: May 7, 2021
|
By:
|
/s/ David Moss
|
|
|
David Moss
|
|
|
Chief Financial Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2023 to Jul 2024